Dongcheng Pharmaceutical announced that on December 31, 2025, the company adopted a plan to repurchase shares through centralized bidding. The repurchase price will not exceed 18 yuan/share, the capital will be 100 million to 200 million yuan, and the period will not exceed 12 months. Recently, the company obtained a “Loan Commitment Letter” from the Yantai branch of China Merchants Bank. The loan will not exceed 170 million yuan, and the term will not exceed 36 months. The letter of commitment is valid until January 5, 2027. This loan does not constitute a related transaction and does not affect the company's operations and performance. The company will implement the repurchase and disclose information in accordance with regulations.

Dongcheng Pharmaceutical announced that on December 31, 2025, the company adopted a plan to repurchase shares through centralized bidding. The repurchase price will not exceed 18 yuan/share, the capital will be 100 million to 200 million yuan, and the period will not exceed 12 months. Recently, the company obtained a “Loan Commitment Letter” from the Yantai branch of China Merchants Bank. The loan will not exceed 170 million yuan, and the term will not exceed 36 months. The letter of commitment is valid until January 5, 2027. This loan does not constitute a related transaction and does not affect the company's operations and performance. The company will implement the repurchase and disclose information in accordance with regulations.